Eisai and Biogen’s Alzheimer’s treatment Leqembi is facing another knockback in Europe.
Last month, the European Medicines Agency rejected the early Alzheimer’s disease treatment on grounds of efficacy, a decision which if...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?